The Journal is included in Russian and International Library and Abstract Databases
Russain Science Index (Russia)
EBSCO
DOI Registration Agency (USA)

Problems in choosing treatment options

DOI: https://doi.org/10.29296/25877305-2020-08-02
Issue: 
8
Year: 
2020

Professor I. Samorodskaya, MD National Medical Research Center for Therapy and Preventive
Medicine, Moscow

The discussion article presents problems in the intuitive and science- and evidence-based application of treatment options. There are no clear criteria between these concepts, just as there are no clear criteria for evidence of the efficiency of treatment. Today, even in the best journals, there are problems with the reliability and correctness of the information placed. The intuitive and theoretically substantiated treatment searches (considered by the example of COVID-19) are quickly transformed into myths and misinformation, including the widespread use of off-label drugs and the misinterpretation of research results on prevention, diagnosis, and treatment methods.

Keywords: 
evidence-based medicine
choice of treatment options
performance criteria
off-label drugs
COVID-19



References: 
  1. «Solidarity» clinical trial for COVID-19 treatments. URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments [Available 22.06.2020].
  2. Schunemann H., Brozek J., Oxman A. GRADE handbook for grading quality of evidence and strength of recommendation. Ontario: The GRADE Working Group, 2013.
  3. Scottish Intercollegiate Guidelines Network (SIGN). URL: http://www.sign.ac.uk/ [Available 22.06.2020].
  4. Prikaz №103 MZ RF ot 28.02.2019 «Ob utverzhdenii porjadka i srokov razrabotki klinicheskih rekomendatsij, ih peresmotra, tipovoj formy klinicheskih rekomendatsij i trebovanij k ih strukture, sostavu i nauchnoj obosnovannosti vkljuchaemoj v klinicheskie rekomendatsii informatsii» [Prikaz №103 MZ RF ot 28.02.2019 «Ob utverzhdenii poryadka i srokov razrabotki klinicheskikh rekomendatsii, ikh peresmotra, tipovoi formy klinicheskikh rekomendatsii i trebovanii k ikh strukture, sostavu i nauchnoi obosnovannosti vklyuchaemoi v klinicheskie rekomendatsii informatsii» (in Russ.)].
  5. ESC. Clinical Practice Guidelines. URL: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines [Available 22.06.2020].
  6. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311 (5): 507–20 DOI: 10.1001/jama.2013.284427
  7. Off-label use of medicines for COVID-19. Scientific brief. URL: https://www.who.int/news-room/commentaries/detail/off-label-use-of-medicines-for-covid-19 [Available 22.06.2020].
  8. Vremennye metodicheskie rekomendatsii «Profilaktika diagnostika i lechenie novoj koronavirusnoj infektsii COVID-19. Versija 7». Minzdrav Rossii [Vremennye metodicheskie rekomendatsii «Profilaktika diagnostika i lechenie novoi koronavirusnoi infektsii COVID-19. Versiya 7». Minzdrav Rossii (in Russ.)]. URL: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf [Available 22.06.2020].
  9. Darrow J.J., Sarpatwari A., Avorn J. et al. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med. 2015; 372 (3): 279–86. DOI: 10.1056/NEJMhle1409465
  10. Sullivan T. Understanding FDA Regulatory Terminology During COVID-19. URL: https://www.fda.gov/consumers/consumer-updates/understanding-regulatory-terminology-potential-preventions-and-treatments-covid-19 [Available 22.06.2020].
  11. International Union for Basic and Clinical Pharmacology (IUPHAR) Clinical Division considerations in the context of COVID-19 pandemics. URL: https://iuphar.org/wp-content/uploads/2020/05/IUPHAR-Clinical-Division-Considerations-in-the-Context-of-COVID-19-Pandemics.pdf [Available 22.06.2020].
  12. Gautret P., Lagier J.C., Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20]. Int J Antimicrob Agents. 2020; 105949. DOI: 10.1016/j.ijantimicag.2020.105949
  13. Frequently Asked Questions on the Emergency Use Authorization (EUA) for Chloroquine Phosphate and Hydroxychloroquine Sulfate for Certain Hospitalized COVID-19 Patients. URL: https://www.fda.gov/media/136784/download [Available 22.06.2020].
  14. Official Statement from International Society of Antimicrobial Chemotherapy (ISAC) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial (Gautret P et al. PMID 32205204) URL: https://www.isac.world/news-and-publications/official-isac-statement [Available 22.06.2020].
  15. Piszczatoski CR. Powell Emergency Approval of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. Ann Pharmacother. 2020: 1060028020925558. DOI: 10.1177/1060028020925558
  16. Omel'janovskij V.V., Antonov A.A., Bezdenezhnyh T.P. i dr. Sistematicheskij obzor aktual'nyh nauchnyh svedenij o primenenii lekarstvennyh preparatov v terapii novoj koronavirusnoj infektsii COVID-19. Meditsinskie tehnologii. Otsenka i vybor. 2020; 1: 8–18 [Omelyanovskiy V.V., Antonov A.A., Bezdenezhnykh T.P. et al. Current Research Data on Drug Therapy for Novel Coronavirus Associated Disease (COVID-19): Systematic Review. Medical Technologies. Assessment and Choice. 2020; 1: 8–18 (in Russ.).]. DOI: 10.31556/2219-0678.2020.39.1.008-018
  17. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020: S0140-6736(20)31180-6. https://doi.org/10.1016/S0140-6736(20)31180-6 .
  18. James Watson on the behalf of 201 signatories (2020, May 28). An open letter to Mehra et al. and The Lancet (Version 4). Zenodo. http://doi.org/10.5281/zenodo.3871094
  19. The Lancet Editors. Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020; 395 (10240): e102. DOI: 10.1016/S0140-6736(20)31290-3
  20. Mehra M.R., Desai S.S., Ruschitzka F. et al. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [published online ahead of print, 2020 May 22] [retracted in: Lancet. 2020 Jun 5;:null]. Lancet. 2020; S0140-6736(20)31180-6. DOI: 10.1016/S0140-6736(20)31180-6
  21. https://www.theglobeandmail.com/world/video-who-set-to-resume-hydroxychloroquine-trial/ [Available 22.06.2020].
  22. O primenenii preparata Gidroksihlorohin dlja lechenija patsientov s koronavirusnoj infektsiej [O primenenii preparata Gidroksikhlorokhin dlya lecheniya patsientov s koronavirusnoi infektsiei (in Russ.)]. URL: https://www.rosminzdrav.ru/news/2020/05/28/14067-o-primenenii-preparata-gidroksihlorohin-dlya-lecheniya-patsientov-s-koronavirusnoy-infektsiey [Ssylka aktivna / Available: 22.06.2020].
  23. Understanding the Regulatory Terminology of Potential Preventions and Treatments for COVID-19. URL: https://www.fda.gov/media/138490/download [Available 22.06.2020].
  24. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020. URL: https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf [Available 22.06.2020].
  25. «Solidarity» clinical trial for COVID-19 treatments URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments [Available 22.06.2020].
  26. Hydroxychloroquine / COVID-19. URL: https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=hydroxychloroquine&cntry=&state=&city=&dist= [Available 22.06.2020].
  27. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. URL: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19 [Available 22.06.2020].
  28. Wang Y., Zhang D., Du G. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [published correction appears in Lancet. 2020 May 30; 395 (10238): 1694]. Lancet. 2020; 395 (10236): 1569–78. DOI: 10.1016/S0140-6736(20)31022-9
  29. FDA. URL: https://www.fda.gov/media/137564/download [Available 22.06.2020].
  30. Recommendations for Hospitalized Patients with Severe COVID-19. URL: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir/ [Available 22.06.2020].
  31. Suzuki H.G., Dewez J.E., Nijman R.G. et al. Clinical practice guidelines for acute otitis media in children: a systematic review and appraisal of European national guidelines. BMJ Open. 2020; 10 (5): e035343. DOI: 10.1136/bmjopen-2019-035343
  32. Dagens A., Sigfrid L., Cai E. et al. Scope, quality, and inclusivity of clinical guidelines produced early in the COVID-19 pandemic: rapid review. BMJ. 2020; 369: m1936. DOI: https://doi.org/10.1136/bmj.m1936. URL: https://www.bmj.com/content/369/bmj.m1936 [Available 22.06.2020].
  33. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/
  34. Smith G.C.S., Pell J.P. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003; 327: 1459. DOI: 10.1136/bmj.327.7429.1459
  35. Rotts M., Prata N., Walsh J.et al. Parachute approach to evidence based medicine. BMJ. 2006; 333: 701. DOI: 10.1136/bmj.333.7570.701. URL: https://www.bmj.com/content/333/7570/701?ijkey=6b4577e0734d5e2589fd478a63132206469106aa&keytype2=tf_ipsecsha [Available 22.06.2020].
  36. Perry Wilson F. COVID-19 Data, Fast and Furious: ‘We Need to Adapt’ URL: https://www.medscape.com/viewarticle/927616 [Available 22.06.2020].
  37. Mandrola J. Some Data May Be Worse Than No Data in the COVID Era. URL: https://www.medscape.com/viewarticle/930504 [Available 22.06.2020].
  38. Zagury-Orly I., Schwartzstein R.M. Covid-19 – A Reminder to Reason [published online ahead of print, 2020 Apr 28]. N Engl J Med. 2020. DOI: 10.1056/NEJMp2009405
  39. Farsalinos K., Barbouni A., Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Intern Emerg Med. 2020; 1–8. DOI: 10.1007/s11739-020-02355-7
  40. France Bans the Online Sale of Nicotine Products. URL: https://tobaccoreporter.com/2020/04/24/france-bans-the-online-sale-of-nicotine-products/ [Available 22.06.2020]. Wang B., Kovalchuk A., Li D. et al. In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues. Preprints. 2020; 2020040315. DOI: 10.20944/preprints202004.0315.v1
  41. Yichang Yang. Use of herbal drugs to treat COVID-19 should be with caution. Lancet. 2020; 395 (10238): 1689–90. https://doi.org/10.1016/S0140-6736(20)31143-0
  42. COVID-19 i Coronavirus fuels a surge in fake medicines. URL: https://www.bbc.com/news/health-52201077 [Available 22.06.2020].
  43. US FDA also published a warning regarding the sale and use of chlorine dioxide products – which when mixed with other chemicals can become bleach – as a prevention or treatment for COVID-19. [Available 22.06.2020].
  44. Ratzan S., Gostin L., Meshkati N. et al. COVID-19: An Urgent Call for Coordinated, Trusted Sources to Tell Everyone What They Need to Know and Do. NAM Perspectives. Commentary, National Academy of Medicine, Washington, DC, 2020. DOI: 10.31478/202003a. URL: https://nam.edu/covid-19-an-urgent-call-for-coordinated-trusted-sources-to-tell-everyone-what-they-need-to-know-and-do/ [Available 22.06.2020].